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Calreticulin (CALR) is a chaperone protein that localizes primarily to the endoplasmic reticulum (ER) lumenwhere it
is responsible for the control of proper foldingof neo-synthesizedglycoproteins and the retentionof calcium.Recently,
mutations affecting exon 9 of the CALR gene have been described in approximately 40% of patients with myelo-
proliferative neoplasms (MPNs). Although the role of mutated CALR in the development of MPNs has begun to be
clarified, there are still no data available on the functionofwild-type (WT)CALRduringphysiological hematopoiesis.
To shed light on the role ofWTCALRduring normal hematopoiesis,we performedgene silencing andoverexpression
experiments in hematopoietic stemprogenitor cells (HSPCs).Our results showed that CALRoverexpression is able to
affect physiological hematopoiesis by enhancing both erythroid and megakaryocytic (MK) differentiation. In
agreement with overexpression data, CALR silencing caused a significant decrease in both erythroid and MK
differentiation of human HSPCs. Gene expression profiling (GEP) analysis showed that CALR is able to affect the
expression of several genes involved in HSPC differentiation toward both the erythroid andMK lineages. Moreover,
GEP data also highlighted the modulation of several genes involved in ER stress response, unfolded protein response
(UPR), and DNA repair, and of several genes already described to play a role in MPN development, such as
proinflammatory cytokines and hematological neoplasm-related markers. Altogether, our data unraveled a new and
unexpected role forCALRin the regulationofnormalhematopoietic differentiation.Moreover, by showing the impact
of CALR on the expression of genes involved in several biological processes already described in cellular transfor-
mation, our data strongly suggest amore complex role forCALR inMPNdevelopment that goes beyond the activation
of the THPO receptor and involves ER stress response, UPR, and DNA repair.
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Introduction
Calreticulin (CALR) is a Ca
2+ binding chaperone lo-
cated in the lumen of the endoplasmic reticulum (ER),
where it plays a critical role in quality control of protein
folding and in Ca2+ storage and release in the ER [1]. CALR
consists of three distinct structural and functional domains:
the N-terminal domain, which together with the proline-rich P-
domain plays a role in chaperone activity, and the C-terminal
domain, which is responsible for Ca2+ homeostasis. The
C-terminal domain also contains a KDEL sequence involved
in preventing release of protein from ER. CALR has also
been found in the cytoplasm, at the cell membrane, and in the
extracellular matrix, where it takes part in many physiolog-
ical processes, such as immune response, cell proliferation
and apoptosis, phagocytosis, wound healing, and fibrosis [2].
In the cytoplasm, CALR has been reported to be asso-
ciated with the C-terminal tail of alpha integrins [3] and
has been demonstrated to affect cell adhesion through the in-
duction of adhesion molecule expression and its involvement
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in beta-catenin-associated pathways [4]. Interestingly, at the
cell surface, CALR has been described to function as ‘‘eat
me signal’’ regulating recognition and removal of apoptotic
cells by professional phagocytes [5].
Recently, two independent groups reported the discovery
of mutations in the CALR gene in myeloproliferative neo-
plasms (MPNs), specifically in 60–80% of JAK2- and MPL-
unmutated essential thrombocythemia (ET) and primary
myelofibrosis (PMF) patients [6,7]. So far, 36 different types
of CALR mutants have been reported in MPNs [6]. All these
mutations, consisting of deletions and/or insertions, lead to a
1-bp frameshift generating an alternative reading frame,
resulting in the loss of most of the acidic C-terminal domain
and the KDEL signal, which might lead to protein mis-
localization and aberrant protein function and stability.
Recently, several reports shed light on the function of
CALR mutants in ET and PMF: Marty et al. [8] established a
retroviral mouse model for CALRins5 and CALRdel52,
showing that CALR mutations are able to induce the devel-
opment of an ET-like phenotype, and in case of CALRdel52,
the progression to myelofibrosis. Moreover, Chachoua et al.
demonstrated the necessity of the thrombopoietin (THPO)
receptorMPL forCALR-mediated cellular transformation [9].
Finally, two research groups have shown physical interaction
ofCALRmutants andMPL;CALRmutations generate a novel
C-terminal domain that enables the N-terminal domain of
CALR to interact with the extracellular domain of MPL,
causing its activation [10,11].
So far, the role of CALR mutations in the development of
MPN has been only partially elucidated, and no data are avail-
able on the physiological function played by CALR during
normal hematopoiesis. The only report available is focused on
the study ofCALRduring stress erythropoiesis [12]: the authors
demonstrated that in normal proerythroblasts, the CALR
C-terminal domain undergoes conformational changes in re-
sponse to Ca2+ that activate the nuclear export of the gluco-
corticoid receptor (GR), resetting the stress response and
allowing the cells to undergo terminal differentiation.
In this study, to unravel the physiological role played by
CALR in normal hematopoiesis, overexpression and gene
silencing experiments have been performed. Our results
demonstrated that CALR expression is able to induce the dif-
ferentiation of hematopoietic stem progenitor cells (HSPCs)
toward the erythroid and megakaryocytic (MK) lineages.
GEP analysis pointed out the activation mediated by CALR
of several signaling pathways involved in erythroid and MK
development and in the regulation of HSC self-renewal.
Moreover, our GEP data showed that CALR also affects the
expression of genes involved in DNA repair, and in ER
stress response and unfolded protein response (UPR). These
data suggest a more complex role for CALR in the devel-
opment of the MPN disease that goes beyond the interaction
and activation of the THPO receptor.
Materials and Methods
Ethics statement
Human CD34+ cells were purified upon donor’s informed
written consent from umbilical cord blood (CB) samples,
collected after normal deliveries, according to the institu-
tional guidelines for discarded material (Clearance of Ethical
Commitee for Human experimentation of Florence: Comitato
Etico Area Vasta dell’Azienda Ospedaliero-Universitaria Car-
eggi, approval date: April 22, 2011, approval file number # 2011/
0014777).
Human CD34+ HSPCs purification
CB CD34+ cells were purified as previously described
[13]. After immunomagnetic separation, CD34+ cells were
seeded in 24-well plates at 5· 105/mL in Iscove’s modified
Dulbecco’s medium (IMDM) (GIBCO, Grand Island, NY)
containing 20% human serum (HS) (Bio-Whittaker, Walkers-
ville, MD), SCF (50 ng/mL), Flt3-ligand (Flt3 L) (50 ng/mL),
THPO (20ng/mL), IL-6 (10 ng/mL), and IL-3 (10ng/mL) (all
from Miltenyi Biotec) and transduced with the retroviral
vector LXIDN or electroporated 24 h later.
Retroviral vectors packaging
The human CALR cDNA (NM_004343) was synthesized
and cloned into retroviral vector LXIDN [14]. Packaging
line for LCALRIDN was generated by transinfection in the
ecotropic Phoenix and amphotropic GP+envAm12 cells, as
previously described [14]. Viral titers were assessed by flow
cytometry analysis of a truncated version of low-affinity
nerve growth factor receptor (DeltaNGFR, DNGFR) ex-
pression percentage upon infection of CB CD34+ cells.
Hematopoietic cell transduction and purification
Transduction of CB CD34+ cells was performed 24h after
isolation. Retroviral transductionwas performed by four cycles
of infection (one every 12h) with viral supernatant with the
addition of polybrene (8mg/mL), 20% HS, and human cyto-
kines (SCF, Flt3-l, THPO, IL-6, and IL-3 as described above) in
retronectin-coated plates. Untreated 24-well plateswere coated
with retronectin (10mg/cm2) (Takara Bio, Inc., Japan) follow-
ing the manufacturer’s protocol. To achieve optimal expansion
and infection of primary CD34+ cells, the retronectin-coated
plateswerepreincubatedwith retroviral supernatant for 4 h, and
then CD34+ cells were seeded in 24-well plate at 3· 105 cells/
mL (1mL/well) in fresh viral supernatant.
After transduction, CB CD34+ cells were maintained in
the above described liquid culture conditions for additional
36 h. Transduced CD34+ cells were subsequently purified by
means of immunomagnetic selection (EasySep ‘‘Do-It-
Yourself’’ Selection Kit; StemCell Technologies) using the
anti-human p75-NGFR mouse monoclonal antibody (BD
Biosciences). Purity of the NGFR+ cell fraction was assessed
by flow cytometry after labeling with PE-conjugated anti-
NGFR monoclonal antibody (Miltenyi) 48 h postpurification
and was always >90%.
Nucleofection of CD34+ cells
Human CD34+ cells were transfected by using the 4D-
Nucleofector" System (Lonza) as previously reported [15].
Briefly, starting from the day after CD34+ cell purification,
each sample was electroporated thrice, once every 24 h, with
a small interfering RNA (siRNA) targeting human CALR
mRNAs (Life Technologies, siRNA ID s115). For each
electroporation, 4 · 105 CD34+ cells were resuspended in
100 mL of P3 Primary Cell Solution (Lonza), containing 3mg
of siRNA, and pulsed with the program DS112. To exclude




































nonspecific effects caused by interfering RNA (RNAi)
nucleofection, a sample transfected with a nontargeting
siRNA (NTsiRNA; Life Technologies) was included. Cells
were analyzed 48 h after the last nucleofection for both cell
viability and CALR mRNA and protein expression.
CD34+ cell culture conditions
For liquid culture differentiation assays, 24 h after the last
nucleofection or immediately after NGFR-positive cell isola-
tion (hereafter reported as postnucleofection and posttransduc-
tion, respectively), CD34+ cells were plated (5· 105/mL) in the
following: (a) multilineage differentiation medium: IMDM
added with 20% BIT serum substitute (bovine serum albu-
min, insulin, and transferrin; StemCell Technologies), sup-
plemented with SCF (50ng/mL), Flt3L (50ng/mL), THPO
(20ng/mL), IL-6 (10ng/mL), and IL-3 (10ng/mL) [15]; (b)
MK differentiation medium: serum-free medium SYN-H
(ABCell-Bio, Paris, France) supplemented with SCF (5ng/mL),
THPO (50ng/mL), IL11 (40ng/mL), IL3 (2ng/mL), and IL6
(1ng/mL) [16]; (c) erythroid differentiation medium: IMDM
added with 20% BIT serum substitute (StemCell Technol-
ogies) supplemented with erythropoietin (EPO; 0.4U/mL;
R&D Systems) and SCF (50 ng/mL; Miltenyi) [17]; (all
cytokines from Miltenyi Biotec). The medium was replaced
every 3 days.
Methylcellulose and collagen clonogenic assays
The methylcellulose assay was carried out by plating CD34+
cells in MethoCult" GF H4434 (StemCell Technologies, Inc.,
Vancouver), as previously described [18]. MK colony-forming
units (CFU-MKs) were assayed in a collagen-based medium,
using a commercial MK assay detection kit (MegaCult-C;
StemCell Technologies, Inc.) as previously reported [18].CFU-
MKs were scored according to the manufacturer’s protocol as
small (3–21 cells, deriving from more mature megakaryocyte
progenitors),medium (21–49 cells), and large (>50cells, arising
from more primitive MK progenitors) colonies based on their
size, which reflects the maturation stage of the progenitor cells
giving rise to each colony.
Morphological and immunophenotypic analysis
Differentiation of CD34+ cells was monitored by mor-
phological analysis of May-Grunwald-Giemsa-stained cy-
tospins and by flow cytometric analysis of differentiation
markers’ expression (Glycophorin A [GPA], CD41, and
CD42b) on day 9, 12, and 14 after the last nucleofection or
retroviral infection. Images were captured by using an
Ax10scopeA1 microscope equipped with AxioCam ERc 5S
Digital Camera and Axion software 4.8 (all Carl Zeiss Mi-
croImaging, Inc., Thornwood, NY). The images were then
processed with Adobe Photoshop 7.0 software. The fol-
lowing monoclonal antibodies (MoAbs) were used for flow
cytometric analysis: FITC-conjugated mouse antihuman CD41
MoAb, PE-conjugated mouse antihuman CD42b MoAb, and
PE-conjugated mouse anti-human GPA MoAb (all from Dako;
Milano, Italia; www.dako.com). After staining, cells were an-
alyzed by using a BD FACSCanto II (BD Biosciences, San
Jose, CA). At least 10,000 events were counted for each sample
to ensure statistical relevance.
Immunofluorescence staining
Cytospins were fixed with 4% paraformaldehyde (PFA)
and permeabilized using 0.3% Triton X-100 in PBS for
20min at room temperature. After blocking with 5% FBS,
2% BSA, and 0.1% Triton X-100 in PBS for 30min at 37#C,
slides were incubated with mouse anti-human CD41a (1:200
in blocking solution, BD Pharmingen"; BD Biosciences, San
Jose, CA) or mouse anti-human Glycophorin A (clone JC159,
1:100 in blocking solution; DakoCytomation, Carpiteria, CA)
overnight at 4#C. This was followed by incubation with
horseradish peroxidase-conjugated goat anti-mouse (1:1,000
in blocking, catalog #sc2005; Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) for 30min at 37#C. All incubations
were followed by three washes with PBS solution. Nuclear
counterstainingwas performedwith 4¢,6-diamino-2-phenylindole
(DAPI). The slides were mounted with the DakoCytomation
fluorescent mounting medium (DAKO). Finally, fluorescence
imaging was performed using the Zeiss LSM 510 Meta
Confocal Microscope (Zeiss, Germany) and digital images of
representative areas were taken. To ensure random sampling,
50 images/slide were captured and cells positive for GPA or
CD41 were scored.
Western blot
CALR protein levels were assessed by means of western
blot analysis in CD34+ cells. Briefly, cells were harvested
48 h after the last nucleofection or immediately after
NGFR-positive cell isolation, washed twice with cold
phosphate-buffered saline (PBS), and lysed in 50mM Tris
(tris(hydroxymethyl) aminomethane)-Cl (pH 7.4), 150mM
NaCl, 1% Nonidet P-40, 10mM KCl, 1mM EDTA, 20mM
NaF, 0.25% Na doexycholate, 5mM dithiothreitol (DTT).
Protease inhibitors (Roche, Indianapolis, IN; Complete,
catalog #1697498) and phosphatase inhibitors (Thermo-
Fisher Scientific) were added to the lysis buffer. Total cel-
lular lysates (30mg for each sample) were loaded and separated
on 10% SDS-polyacrylamide gel and then transferred onto a
nitrocellulose membrane. To visualize loading and transfer,
Ponceau staining has been performed. Membranes were then
preblocked in a blocking solution of 0.1% TBST containing
5% non-fat dry milk (NFDM) and then incubated with the
following primary antibodies: rabbit policlonal anti-CALR
antibody (Abcam; catalog# ab2907, 1:250 dilution at 4#C
overnight) and rabbit polyclonal anti-b-actin primary anti-
body (Thermo Fisher Scientific Inc, catalog #PA1-16889;
1:2,000 dilution for 1 h at RT). The blots were washed three
times with 0.1% TBST and then incubated with 1:1,000
dilution of HRP-conjugated goat anti-rabbit secondary an-
tibody (Thermo Fisher Scientific, Inc.; catalog #32460) for
1 h at RT in secondary antibodies. After three successive
washes with TBS, BM chemiluminescence blotting sub-
strate (POD) (Roche) was used for protein detection.
RNA extraction
Total cellular RNA was harvested from 1· 105 cells from
each sample using the miRNeasy Micro RNA isolation kit
(QIAGEN) according to the manufacturer’s instructions. RNA
sample concentration and purity (assessed as 260/280 nm and
260/230 nm ratios) were evaluated by NanoDrop ND-1000
spectrophotometer (NanoDropTechnologies,Wilmington,DE),




































while RNA integrity was assessed by using the Agilent 2100
Bioanalyzer (Agilent Technologies, Waldbrunn, Germany).
Quantitative reverse transcription–polymerase
chain reaction
Total RNA (100 ng) was reverse transcribed to cDNA
using a High Capacity cDNA Archive Kit (Life technolo-
gies; Carlsbad, CA). TaqMan PCR was carried out using the
TaqMan Fast Advanced PCR master mix and TaqMan gene
expression assays (all reagents from Life Technologies) by
means of a 7900HT Fast Real-Time PCR System (Applied
Biosystems). Assays were performed in triplicate. Gene
expression profiling (GEP) was achieved using the com-
parative cycle threshold (CT) method of relative quantita-
tion using Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) as housekeeping genes. To normalize data, DDCT
was calculated for each sample using the mean of its DCT
values subtracted from the mean DCT value measured in the
control sample, set as a calibrator; relative quantitation (RQ)
value was expressed as 2-DDCT.
Gene expression profiling
GEP was performed on RNA samples isolated from
NGFR-positive cells purified after retroviral transduction
from the samples transduced with the empty control vector
LXIDN (LXIDN), and from the samples transduced with
the vector carrying CALR cDNA (LCALRIDN) (three
independent experiments). GEP cDNA synthesis and biotin-
labeled target synthesis were performed using the Gene-
Chip$ 3¢ IVT PLUS Reagent Kit according to the protocol
supplied by Affymetrix. The HG-U219 Array Strips (Affy-
metrix, Santa Clara, CA) hybridization, staining, and scan-
ning were performed by using the GeneAtlas Platform.
Robust multiarray average procedure was used to perform
probe-level normalization and conversion into expression val-
ues [19]. Differentially expressed genes (DEGs) were then
selected following a supervised approach with the analysis of
variance (ANOVA) module supplied by the Partek GS. 6.6
Software Package (www.partek.com). We consider as differ-
entially expressed all the probesets with a fold change contrast
‡1.5 in the pairwise comparison between LCALRIDN versus
LXIDN samples and a P-value £0.05.
In the same way, GEP was performed on RNA samples
isolated from CALR-silenced (CALRsiRNA sample) and
non-targeting negative control siRNA-transfected (NTsiR-
NA sample) CD34+ cells 24 h after last nucleofection from
three independent experiments. GEP data were analyzed by
using the Partek GS 6.6 Software Package as reported
above, by selecting the probesets with a fold change contrast
‡1.5 (P< 0.05) as DEGs in the pairwise comparison between
CALR siRNA and NTsiRNA samples.
Raw and normalized GEP data have been submitted to the
NCBI’s Gene Expression Omnibus (GEO) public repository
[20] (www.ncbi.nlm.nih.gov/geo; series GSE97809).
Statistical analysis
The statistics used for data analysis was based on two-
tailed Student t-tests for average comparisons in paired
samples (equal variance). Data were analyzed with Micro-
soft Excel (Microsoft Office, 2011 release) and are reported
as mean – standard error of the mean (SEM). A P-value
<0.05 was considered significant.
Results
CALR overexpression in CD34+ HSPCs
To characterize the role of CALR in the proliferation and
differentiation of HPSCs, we investigated the effects induced
by CALR overexpression in normal CB CD34+ cells. To this
end, we constructed the LCALRIDN retroviral vector expres-
sing the full-length CALR cDNA and DLNGFR as reporter
gene, in the context of a bicistronic transcript driven by the viral
LTR [14]. Freshly isolated CB CD34+ cells were transduced
with either LCALRIDN vector or the empty control vector and
cell viability was assessed by trypan blue exclusion assay. No
significant differences among LXIDN and LCALRIDN after
four cycles of infection were found (data not shown).
In a set of five independent experiments, gene transfer ef-
ficiency, assessed by flow cytometric analysis of DLNGFR
positivity, ranged from 25% to 33%. Transduced cells were
then purified by nerve growth factor receptor (NGFR) ex-
pression 36h post-infection. Real-time qPCR and western blot
analysis performed on transduced/NGFR-purified cells showed
a significant increase in both mRNA (RQ–SEM, 5.7–1.4,
P< 0.05) and protein levels in LCALRIDN-transduced cells
compared to the control empty vector (Fig. 1A, B).
Biological Effects exerted by CALR overexpression
in CD34+ HSPCs
To shed light on the biological role played by CALR during
hematopoietic commitment and differentiation, CALR cDNA
was overexpressed in CB-derived HSPCs and the biological ef-
fects exerted by its overexpression were assessed by means of in
vitro differentiation assays. Flow cytometry analysis clearly
shows that CALR overexpression did not affect granulocyte or
mono/macrophage differentiation, as demonstrated by the un-
changed expression of granulocyte (ie,CD66b,CD15, andMPO)
or monocyte/macrophage markers (ie, CD14 and CD163)
(Fig. 1C, D, panels).
Since the presence of HS inhibits erythroid and MK dif-
ferentiation of HSPCs in vitro, the effects of CALR over-
expression on erythroid and MK differentiation were evaluated
in serum-free culture conditions by assessing the expression of
the erythroid marker GPA and the MK markers CD41 and
CD42b. Flow cytometry analysis showed a statistically sig-
nificant increase in the percentage of GPA-positive cells as-
sociated with CALR overexpression (Fig. 1E). Moreover, our
data also revealed a statistically significant increase in the
fraction of CD41+ and CD42b+ MK cells in the sample
transduced with LCALRIDN vector compared to the control
sample (Fig. 1F, G).
In agreement with liquid culture results, methylcellulose-
based clonogenic assay showed a significant increase in the
percentage of erythroid colonies (BFU-E and CFU-E) upon
CALR overexpression, while no statistically significant dif-
ferences in myeloid colonies were noticed (CFU-G, CFU-M,
and CFU-GM) (Fig. 1H). The collagen-based clonogenic as-
say demonstrated a significant increase in the percentage of
CFU-MK colonies coupled to a decrease in the non-MK ones
in the LCALRIDN sample compared to the control (Fig. 1I).
Moreover, morphological analysis of May-Grunwald-Giemsa-




































FIG. 1. Effects of CALR overexpression on HSPC differentiation. (A) CALR expression levels 24 h after the last transduction
as evaluated by qRT-PCR. Data are reported as RQmean–SEM of three independent experiments. (B)Western blot analysis of
CALR protein levels in whole cell lysates from CD34+ cells 48 h after last transduction. CALR protein level in LCALRIDN
CD34+ cells was compared with control sample transduced with the LXIDN empty vector. b-actin was included as loading
control. (C) Bar graphs representing the statistical analysis for the flow cytometry evaluation of the granulocytic markers CD15,
MPO, and CD66b in CB CD34+ cells overexpressing CALR (gray bars) and control cells (LXIDN, black bars). (D) Bar graphs
representing the statistical analysis for the flow cytometry evaluation of the mono/macrophage markers CD14 and CD163 in CB
CD34+ cells overexpressing CALR (gray bars) and control cells (LXIDN, black bars). (E) Bar graphs representing the statistical
analysis for the flow cytometry evaluation of the erythroid marker GPA inCBCD34+ cells overexpressing CALR (gray bars) and
control cells (LXIDN, black bars). Marker expression was assessed on days 9, 10, and 13 of serum-free erythroid unilineage cell
culture (n= 3). (F, G) Bar graphs representing the statistical analysis for the flow cytometry evaluation of CD41 (F) and CD42b
(G) cell markers in CB CD34+ cells overexpressing CALR (gray bars) and control cells (LXIDN, black bars). Marker expression
was assessed on days 13, 15, 16, and 17 of serum-free unilineage cell culture (n= 3). (H) Results of the statistical analysis of
methylcellulose clonogenic assay of CB CD34+ cells overexpressing CALR. Cells were plated 24h after last transduction and
colonies were scored on day 14 (n= 3). Results are reported as mean–SEM *P< 0.05. (I) Results of the statistical analysis of
collagen-based clonogenic assay of CB CD34+ cells overexpressing CALR. Cells were seeded in semisolid culture medium 24 h
after the last transduction and colonies were scored after 11 days (n= 3). Results are reported as mean–SEM **P< 0.01;
*P< 0.05. CALR, calreticulin; CFU, colony-forming unit; BFU, burst-forming unit; E, erythroid; GM, granulo-monocyte; G,
granulocyte; M, monocyte; GEMM, granulocyte, erythrocyte, macrophage, megakaryocyte; MK, megakaryocyte; MIX, mixed;





































stained cytospins and immunofluorescent analysis performed
on days 9, 13, and 15 of liquid culture revealed that CALR
overexpression lead to a strong enrichment in erythroid and
MK precursors at different stages of maturation (Fig. 2A, B).
Gene expression profile of CALR-overexpressing
CD34+ cells
To better characterize the molecular mechanisms underlying
the biological effects of CALR overexpression on erythroid and
MK differentiation, we carried out a microarray-based gene
expression analysis on NGFR-positive cells purified after ret-
roviral transduction (Methods section) to compare CALR-
overexpressing cells vs LXIDN-transduced cells. The list of
54 DEGs is shown in Supplementary Table S1 (Supple-
mentary Data are available online at www.liebertpub.com/
scd). Figure 3A shows the hierarchical clustering of LXIDN
and LCALRIDN samples based on the list of 54 DEGs.
Functional analysis by means of Ingenuity Pathway analysis
software (IPA, version 8.6; Ingenuity Systems, Redwood City,
CA, www.ingenuity.com) identified several categories of DEGs,
such as platelet aggregation, proinflammation genes, erythrocyte
differentiation, and several cancer markers already known in
both solid and hematological neoplasms. In particular, among
upregulated genes, we found genes involved in platelet activa-
tion and aggregation, such as SGK1 [21], CD9 [22], FN1 [23],
and THBS1 [24]; genes involved in proinflammatory mecha-
nisms such as chemokines CCL2 [25], CCL3 [26], and CXCL5
[27] and cytokines like IL8 [27]; genes involved in erythrocyte
differentiation such as RHCE [28] and HBZ [29]; and several
FIG. 2. Morphological and
immunofluorescent analyses
of LXIDN and LCALRIDN
samples. (A) Representative
morphological analysis of
LXIDN (i) andLCALRIDN (ii)
samples after May-Grunwald-
Giemsa staining on day 7 of
erythroid unilineage culture.
Arrows point to polychromatic
and orthochromatic erythro-
blasts. Representative morpho-
logical analysis of LXIDN (iii)
and LCALRIDN (iv) samples
after May-Grunwald-Giemsa
stainingon day 13of serum-free
multilineage culture. Arrows
point to megakaryoblasts. Ima-
gesobtainedwith40Xobjective.
(B) Immunofluorescence analy-
sis of GPA and CD41 antigen
on LXIDN and LCALRIDN
samples. Cells were labeled
with anti-human GPA antibody
(greenfluorescence, panels i and
ii) and with anti-human CD41
antibody (green fluorescence,
panels iii and iv); nuclear coun-
terstaining was performed with
DAPI (blue fluorescence). Ima-
gesobtainedwith40·objective.




































cancer markers already known in both solid and hematological
malignancies such as EMP1 [30], VSIG4 [31], and LEP [32]
(Fig. 3B and Supplemntary Fig. S1A).
CALR silencing in CD34+ HSPCs
To confirm the role played by CALR in the regulation of
megakaryocytopoiesis and erythropoiesis, CALR silencing
experiments were performed. To this end, CB CD34+ cells
were transfected with either CALR siRNA (CALR siRNA
sample) or a non-targeting control siRNA (NT siRNA sam-
ple). Real-time quantitative reverse transcription–polymerase
chain reaction (qRT-PCR) and western blot analysis, per-
formed, respectively, 24 and 48 h after last nucleofection,
confirmed CALR downregulation both at the mRNA
(RQ – SEM, 0.12– 0.014, P < 0.001) and protein level in the
CALR siRNA sample compared to the control (Fig. 4A, B).
Flow cytometric analysis of myeloid lineage differentia-
tion markers showed no difference in the expression level of
either granulocytic (ie, CD66b, CD15, and MPO) or mono/
macrophage (ie, CD14 and CD163) markers in CALR
siRNA sample compared to the control (Fig. 4C, D). On the
other hand, results from multilineage and EPO-driven cul-
tures, clearly demonstrated a strong effect induced by
CALR silencing on both MK and erythroid commitment. As
for the erythroid differentiation, we observed a steady de-
crease of the erythroid marker GPA in CALR-silenced cells
compared to control cells (Fig. 4E). Strikingly, our data
showed a significant decrease in the expression of the MK
markers CD41 and CD42b in CALR-silenced cells com-
pared to the negative control sample (Fig. 4F, G).
To better characterize the role of CALR in HSPC dif-
ferentiation, cells were plated in methylcellulose-based
medium 24 h after the last nucleofection. Methylcellulose
clonogenic assay showed no statistically significant differ-
ence in the percentage of myeloid colonies (CFU-G, CFU-
GM, CFU-M, and CFU-GEMM) in CALR-silenced cells
compared to the negative control cells. On the other hand,
CALR silencing was able to induce a statistically significant
decrease in the percentage of erythroid colonies (BFU-E &
CFU-E) compared to the control sample (Fig. 4H).
To assess the effect mediated by CALR silencing on MK
differentiation, a collagen-based clonogenic assay supporting
megakaryocyte progenitor growth in vitro was performed.
Results showed a significant decrease in the percentage ofMK
colonies coupled to an increase in the percentage of non-MK
and mixed colonies in samples transfected with CALR siRNA
compared to the control (Fig. 4I). Morphological analysis of
May-Grunwald-Giemsa-stained cytospins and immunofluo-
rescent analysis confirmed that CALR silencing led to a de-
crease in the number of MK and erythroid precursors in
unilineage MK and erythroid cultures, respectively (Fig. 5A,
B). Altogether, our data demonstrated that CALR silencing is
able to inhibit MK and erythroid differentiation of HSPCs, in
agreement with the results obtained in CALR overexpression
experiments.
Gene expression profile of CALR-silenced
CD34+ cells
To shed light on the molecular mechanisms supporting
the biological effects exerted by CALR silencing, GEP
FIG. 3. Effects of CALR overexpression on HSPC gene expression profile. (A) Hierarchical clustering of LXIDN and
LCALRIDN samples based on the list of 54 differentially expressed transcripts. (B) Histogram chart of a selection of the
most significant differentially expressed genes in the comparison LCALRIDN versus LXIDN.




































FIG. 4. Effects of CALR silencing on HSPC differentiation. (A) CALR expression levels 24 h after the last nucleofection as
evaluated by qRT-PCR. Data are reported as RQ mean–SEM of three independent experiments. (B) Western blot analysis of
CALR protein levels in whole cell lysates from CD34+ cells 48 h after last nucleofection. CALR protein level in CALR siRNA
CD34+ cells was compared with control sample transfected with the non-targeting siRNA. b-actin was included as loading
control. (C) Bar graphs representing the statistical analysis for the flow cytometry evaluation of granulocytic markers CD15,
MPO, and CD66b in CALR siRNA CD34+ cells (gray bars) and NTsiRNA cells (black bars). (D) Bar graphs representing the
statistical analysis for the flow cytometry evaluation of the mono/macrophage markers CD14 and CD163 in CALR siRNA
CD34+ cells (gray bars) and NTsiRNA cells (black bars). (E) Bar graphs representing the statistical analysis for the flow
cytometry evaluation of the erythroid marker GPA in CALR siRNA CD34+ cells (gray bars) and NTsiRNA cells (black bars).
Marker expression was assessed on days 8, 11, and 13 of serum-free erythroid unilineage cell culture (n= 3). (F, G) Bar graphs
representing the statistical analysis for the flow cytometry evaluation of CD41 (F) and CD42b (G) cell markers in CALR siRNA
CD34+ cells (gray bars) and NT siRNA cells (black bars). Marker expressionwas assessed n days 7, 11, 13, and 15 of serum-free
multilineage cell culture (n= 3). Results are reported as mean–SEM *P£ 0.05. (H) Results of the statistical analysis of
methylcellulose clonogenic assay of CALR-silenced CD34+ cells. Cells were plated 24h after last nucleofection and colonies
were scored on day 14 (n= 3). Results are reported as mean–SEM *P< 0.05. (I) Results of the statistical analysis of collagen-
based clonogenic assay of CALR-silenced CD34+ cells. Cells were seeded in semisolid culture medium 24h after the last





































analysis was performed on CALR-silenced cells (CALR-
siRNA sample) and non-targeting negative control siRNA-
transfected cells (NTsiRNA sample). The list of 154 DEGs
is shown in Supplementary Table S2. Figure 6A shows the
hierarchical clustering of NTsiRNA and CALRsiRNA
samples based on the list of 154 DEGs.
Functional analysis by means of Ingenuity Pathway
analysis software identified several categories of DEGs,
such as ER stress, UPR, proliferation of blood cells, quantity
of myeloid cells, quantity of hematopoietic progenitor cells,
and DNA repair. In particular, among upregulated genes
(Fig. 6B and Supplementary Fig. S1B), we found genes
involved in UPR and ER stress response, such as Heat
Shock Protein 90 kDa Beta 1 (HSP90B1) [33], Heat Shock
70 kDa Protein 5 (HSPA5) [34], and selenoprotein K (SELK)
[35] and in the regulation of self-renewal of hematopoietic
stem cells (HSCs) such as cAMP responsive element mod-
ulator (CREM) [36] and kinesin family member 3A (KIF3A)
[37], and hematological malignancies markers such as
MANSC domain containing 1 (MANSC1) [38] and carbonic
anhydrase II (CA2) [39].
On the other hand, among downregulated genes (Fig. 6B),
we found genes involved in DNA repair such as nuclear
casein kinase and cyclin-dependent kinase substrate 1
(NUCKS1) [40] and ubiquitin-conjugating enzyme E2
variant 2 (UBE2 V2) [41]. Altogether, GEP results sug-
gest a role for CALR in several biological processes,
some of which, such as ER stress response and UPR,
might have been inferred from the role of chaperone that
CALR plays in the ER, while some others were unex-
pected, such the involvement in DNA repair or in HSC
self-renewal.
FIG. 5. Morphological and
immunofluorescent analyses of
LXIDN and LCALRIDN sam-
ples. (A) Representative mor-
phological analysis of NT
siRNA (i)andCALRsiRNA (ii)
samples after May-Grunwald-
Giemsa staining on day 7 of
erythroid unilineage culture.
Images obtained with 40· ob-




NT siRNA (iii) and CALR
siRNA (iv) samples after May-
Grunwald-Giemsa staining
on day 13 of serum-free mul-
tilineage culture. Magni-
fication, · 400. Arrows point
to megakaryoblasts. (B) Im-
munofluorescence analysis of
GPA and CD41 antigen on
NTsiRNA and CALRsiRNA
samples. Cells were labeled
with anti-human GPA anti-
body (green fluorescence,
panels i and ii) and with anti-
human CD41 antibody (green
fluorescence, panels iii and
iv); nuclear counterstaining
was performed with DAPI
(blue fluorescence). Images
obtained with 40· objective.





































Recently, the discovery of mutations affecting theCALR gene
has filled a gap regarding the genomic abnormalities responsible
for roughly 60–80% of the JAK2- andMPL-unmutated ETs and
PMFs. CALR mutations have been demonstrated to induce the
development of an ET-like phenotype, progressing to myelofi-
brosis in case of CALRdel52 in a retroviral mouse model [8].
Moreover, mutated CALR has been shown to bind to the THPO
receptor MPL, causing its dimerization and activation and thus
leading to the constitutive activation of JAK2 signaling pathway
[10,11]. This has established an important link between CALR,
MPL, and JAK2 in the pathogenesis of CALR-mutated MPNs.
So far, most of the research efforts have been focused on
the understanding of the role played by mutated CALR in
the development of MPNs. Before the discovery of CALR
mutations in 2013, no involvement of CALR has ever been
suggested in the context of physiological hematopoiesis, and
currently no data are available on the function of CALR
during the hematopoietic development.
To shed some light on CALR function during physiological
hematopoiesis, we performed overexpression and gene silenc-
ing experiments in CD34+HSPCs isolated from normal donors.
CALR has been overexpressed in CD34+ cells by means of
retroviral-mediated gene transfer, and its effects on hemato-
poietic progenitor cell differentiation have been assessed both in
liquid and semisolid cultures.
Our results unravel a new and unexpected role for CALR
in the differentiation of CD34+ cells. In particular, liquid
culture differentiation assays showed that CALR over-
expression in CD34+ cells enhances the expression of both
erythroid and MK lineage markers. In agreement with liquid
culture results, methylcellulose-based and collagen-based
clonogenic assays showed a significant increase in the per-
centage of the erythroid and MK colonies, respectively,
in CALR-overexpressing cells compared to the controls.
Moreover, GEP analysis unveiled the upregulation in
CALR-overexpressing CD34+ cells of several genes in-
volved in erythroid differentiation, such as RHCE [28] and
HBZ [29], and in platelet activation, such as SGK1 [21],
CD9 [22], FN1 [23], and THBS1 [24]. These results support
the role of wild-type CALR in the regulation of physio-
logical hematopoiesis enhancing differentiation toward the
erythroid and MK lineages. Furthermore, our GEP data
pointed out the upregulation of several proinflammatory
genes, such as the chemokines CCL2 [25], CCL3 [26], and
CXCL5 [27], and cytokines like IL8 [27], and cancer-related
markers already described in hematological neoplasms, such
as EMP1 [30], VSIG4 [31], and LEP [32].
These data suggest that CALR expression in HSPCs is
able to induce the expression of several genes that have
already been described to play a role in the development of
MPNs, this in turn implies that CALR might contribute to
the pathogenesis of the MPN disease not only through the
above-mentioned interaction with THPO receptor but also
by enhancing erythroid and MK differentiation together
with inducing the expression of proinflammatory cytokines
already described to be responsible for the development of
BM fibrosis that characterizes PMF.
In agreement with the overexpression results, CALR si-
lencing inCD34+ cells significantly inhibited both erythroid and
MK differentiation. Our data showed that CALR silencing
causes a significant decrease in the percentage of cells positive
for the erythroidmarkerGPAaswell as a significant decrease in
the percentage of cells expressing the MK markers CD41 and
CD42b. The inhibition of erythroid andMK differentiationwas
also confirmed by morphological analysis of May-Grunwald-
Giemsa-stained cytospins, which evidenced in CALR-silenced
FIG. 6. Effects of CALR silencing on HSPC differentiation on gene expression profile. (A) Hierarchical clustering of
NTsiRNA and CALRsiRNA samples based on the list of 154 differentially expressed transcripts. (B) Histogram chart of a
selection of the most significant differentially expressed genes in the comparison CALRsiRNA vs NTsiRNA.




































cells adecrease inpolychromatic andorthochromatic erythtoblasts
in erythroid unilineage culture and a decrease in the number of
megakaryoblasts in THPO-driven culture.
According with liquid culture data, methylcellulose-based
and collagen-based clonogenic assays demonstrated a sig-
nificant decrease in the percentage of erythroid and MK
colonies, respectively, upon CALR silencing.
Moreover, GEP analysis unravels several signaling path-
ways modulated after CALR silencing, such as ER stress re-
sponse, UPR, and DNA repair. Among upregulated genes upon
CALR silencing, we found genes involved in UPR and ER
stress response such as, HSP90B1 [33], HSPA5 [34], and SELK
[35], genes involved in the regulation of self-renewal of HSCs
such as CREM [36] and KIF3A [37]. Among downregulated
genes, we found genes involved in DNA repair such as
NUCKS1 [40] and UBE2 V2 [41]. GEP results after CALR
silencing confirm a role of CALR in ER stress response and
UPR, exemplified by the differential expression of HSP90B1,
HSPA5, and SELK. In addition, GEP results disclose a possible
role of CALR in DNA repair or in HSC self-renewal, which
might have not been foreseen otherwise.
Altogether, our results suggest a role for CALR during
physiological hematopoiesis: CALR expression may affect
HSPC differentiation toward the erythroid and MK lineages.
Moreover, GEP analysis suggested that CALR modulates the
expression of several genes involved in ER stress response,
UPR, and DNA repair, and of several genes that have already
been described to play a role in the development of MPNs,
such as proinflammatory chemokines and hematological
neoplasm-related markers.
To our knowledge, this is the first report describing the
role of WT CALR in hematopoiesis. Moreover, our data are
strongly suggestive of an additional role for CALR in the
development of the MPN disease. So far, the oncogenic role
for CALR mutants has been linked only to the binding of
mutated CALR to the THPO receptor and its consequent
JAK2 pathway activation. Our data pointed out a role for
WT CALR in the induction of MK and erythroid differen-
tiation, which are the two main lineages affected in the
Philadelphia-negative classical MPNs.
Moreover, we also showed a role for CALR in several
biological processes, which might take part in the patho-
genesis of MPNs such as the expression of proinflammatory
cytokines, or the involvement in ER stress response, UPR,
and DNA repair, processes that have been already described
to be linked to cellular transformation and oncogenesis. This
work sheds light on the physiological function of WT CALR
during hematopoiesis and moreover suggests novel path-
ways that might be affected by CALR mutations that have
not been investigated yet.
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